Loading verified market, valuation, and statement data.
2. Company Fundamentals
2.3 Management
| Role |
Metric |
| Consensus Rating |
N/A |
2.4 Return
| Metric |
Value |
| Expected Return (Ann.)* |
5.80% |
| Risk / Std Dev (Ann.)* |
33.17% |
| 1-Year Price Return* |
0.17% |
Latest Market Data (as of 2026-08-14, Hong Kong time):
| Metric |
Value |
| Last Price |
HK$6.89 |
| 52-Week Range |
HK$6.09 – HK$11.74 |
| Observation Count |
245 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
DuPont Model Analysis
The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:
ROE = Net Margin × Asset Turnover × Equity Multiplier
The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.
| DuPont component |
Calculation |
FY2025 |
FY2024 |
| Revenue |
Reported revenue |
HK$50.28B |
HK$48.30B |
| Net income |
Reported net income |
HK$3.84B |
HK$3.14B |
| Total assets |
Year-end reported balance |
HK$84.46B |
HK$82.95B |
| Shareholders’ equity |
Year-end reported balance |
HK$46.57B |
HK$43.80B |
| Net margin |
Net income ÷ revenue |
7.64% |
6.49% |
| Asset turnover |
Revenue ÷ total assets |
0.5953x |
0.5823x |
| Equity multiplier |
Total assets ÷ shareholders’ equity |
1.8136x |
1.8939x |
| ROE |
Net margin × asset turnover × equity multiplier |
8.25% |
7.16% |
Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.
2.5 FCFF DCF Valuation
Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.
Step 1 — Forecast Operating Profit and NOPAT
| Reported operating input |
Value |
| Revenue |
HK$50.28B |
| Prior annual revenue |
HK$48.30B |
| EBIT |
HK$5.75B |
| Tax rate |
20.61% |
| NOPAT = EBIT × (1 − tax rate) |
HK$4.57B |
| Forecast start-growth basis |
4.10% |
| Forecast policy |
latest reported annual revenue growth, bounded to -10.00% / 15.00% |
Step 2 — Calculate FCFF
| Current FCFF building block |
Value |
| NOPAT |
HK$4.57B |
| Add: depreciation & amortisation |
HK$5.70B |
| Less: capital expenditure |
-HK$5.89B |
| Less/(add): working-capital cash-flow movement |
-HK$422.91M |
| Current unlevered FCFF |
HK$3.95B |
Explicit FCFF forecast
| Forecast year |
Revenue growth |
NOPAT |
D&A |
Capex |
Change in NWC |
FCFF |
Present value |
| 1 |
4.10% |
HK$4.75B |
HK$5.93B |
-HK$6.13B |
-HK$440.25M |
HK$4.11B |
HK$3.99B |
| 2 |
3.70% |
HK$4.93B |
HK$6.15B |
-HK$6.31B |
-HK$456.54M |
HK$4.32B |
HK$3.93B |
| 3 |
3.30% |
HK$5.09B |
HK$6.35B |
-HK$6.46B |
-HK$471.61M |
HK$4.51B |
HK$3.87B |
| 4 |
2.90% |
HK$5.24B |
HK$6.54B |
-HK$6.59B |
-HK$485.29M |
HK$4.70B |
HK$3.79B |
| 5 |
2.50% |
HK$5.37B |
HK$6.70B |
-HK$6.70B |
-HK$497.42M |
HK$4.87B |
HK$3.69B |
Step 3 — Determine the Discount Rate (WACC)
| WACC input |
Value |
| Risk-free rate |
4.71% |
| Equity risk premium assumption |
5.50% |
| Beta |
0.60 |
| Cost of equity |
8.03% |
| Pre-tax cost of debt |
3.66% |
| WACC |
6.36% |
| WACC validation |
requires assumption review |
Step 4 — Estimate Terminal Value
| Terminal-value input |
Value |
| Perpetuity growth rate |
2.50% |
| Terminal value |
HK$129.30B |
| Implied terminal EV / EBITDA |
9.60x |
| Terminal value as % of enterprise value |
83.14% |
Step 5 — Discount Cash Flows to Enterprise Value
| Enterprise-value component |
Value |
| Present value of explicit FCFF |
HK$19.26B |
| Present value of terminal value |
HK$94.98B |
| Indicated enterprise value |
HK$114.25B |
| Discounting convention |
mid-year for explicit FCFF; terminal value discounted at year-end five |
Step 6 — Convert Enterprise Value to Equity Value
| Equity bridge |
Value |
| Indicated enterprise value |
HK$114.25B |
| Less: gross interest-bearing debt |
HK$16.89B |
| Add: cash and equivalents |
HK$13.08B |
| Add: affiliate investments |
HK$0.00 |
| Less: minority interests |
HK$577.96M |
| Indicated common equity value |
HK$109.86B |
Step 7 — Calculate Indicative Value Per Share
| Per-share output |
Value |
| Shares used |
1,811,124,000.00 |
| Share-count basis |
reported shares outstanding; option/RSU dilution data not separately available |
| Current market price |
HK$7.34 |
| DCF indicative value per share |
HK$60.66 |
| Indicative value vs. market price |
726.38% |
Model Integrity Checks
| Check |
Result |
| Perpetuity growth is below the risk-free rate |
pass |
| Perpetuity growth is below WACC |
pass |
| WACC is within the configured operating-company range |
review required |
| Terminal-year FCFF is positive |
pass |
| Terminal capex converges to D&A |
pass |
| Terminal-value concentration |
within review band |
| Implied price differs from spot by more than 30% |
review required |
2.6 Investor-Style Research Screen
| Educational screen |
Result |
| Buffett-inspired cash-quality checks |
4/4 evidenced checks |
| Lynch-inspired balance-and-growth checks |
4/4 evidenced checks |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:05:04.266759 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input |
Value |
| Regional factor set |
Asia Pacific ex Japan |
| Factor-return currency |
USD |
| Issuer-return basis |
USD adjusted total return |
| Estimation window |
2025-08-20 to 2026-06-30 |
| Aligned daily observations |
210 |
| Minimum observation requirement |
120 |
| Currency conversion for HK listings |
HKD adjusted close divided by daily USD/HKD close before simple daily return calculation |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic |
FF3 |
FF5 |
| Annualised alpha |
-25.05% |
-24.29% |
| Adjusted R² |
0.08 |
0.07 |
| Annualised residual volatility |
32.13% |
32.11% |
| Factor loading (t-statistic) |
FF3 |
FF5 |
| Market excess return (Mkt-RF) |
0.51 (2.81) |
0.51 (2.58) |
| Size (SMB) |
0.34 (1.28) |
0.32 (0.93) |
| Value (HML) |
1.06 (4.18) |
1.01 (3.58) |
| Profitability (RMW) |
NM |
-0.16 (-0.44) |
| Investment (CMA) |
NM |
-0.01 (-0.03) |
Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.